James A Karlowsky

Summary

Publications

  1. doi In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013
    J A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Electronic address
    Diagn Microbiol Infect Dis 80:311-5. 2014
  2. doi Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    J Antimicrob Chemother 68:i39-46. 2013
  3. doi In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study
    James A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
    Diagn Microbiol Infect Dis 69:342-7. 2011
  4. doi Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11
    Andrew J Denisuik
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    J Antimicrob Chemother 68:i57-65. 2013
  5. doi Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 62:67-80. 2008
  6. doi New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 70:859-86. 2010
  7. pmc Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008)
    George G Zhanel
    Clinical Microbiology, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 54:4684-93. 2010
  8. pmc Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study
    James A Karlowsky
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, St Boniface General Hospital, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 55:3169-75. 2011
  9. doi Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:364-9. 2009
  10. pmc Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 52:1430-7. 2008

Collaborators

Detail Information

Publications56

  1. doi In vitro activity of oritavancin against Gram-positive pathogens isolated in Canadian hospital laboratories from 2011 to 2013
    J A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada Electronic address
    Diagn Microbiol Infect Dis 80:311-5. 2014
    ..2% oritavancin-susceptible), Streptococcus agalactiae (n=156; oritavancin MIC90, 0.12 μg/mL; 100% oritavancin-susceptible), and Enterococcus faecalis (n=304; oritavancin MIC90, 0.06 μg/mL; 98.7% oritavancin-susceptible) tested...
  2. doi Changes in fluoroquinolone resistance over 5 years (CANWARD 2007-11) in bacterial pathogens isolated in Canadian hospitals
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    J Antimicrob Chemother 68:i39-46. 2013
    ....
  3. doi In vitro activity of dalbavancin and telavancin against staphylococci and streptococci isolated from patients in Canadian hospitals: results of the CANWARD 2007-2009 study
    James A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
    Diagn Microbiol Infect Dis 69:342-7. 2011
    ..Based on their robust in vitro activities, dalbavancin and telavancin have the potential to treat Gram-positive infections caused by methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae...
  4. doi Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11
    Andrew J Denisuik
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    J Antimicrob Chemother 68:i57-65. 2013
    ....
  5. doi Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada: Canadian National Intensive Care Unit Study, 2005/2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 62:67-80. 2008
    ..aeruginosa), respectively...
  6. doi New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 70:859-86. 2010
    ....
  7. pmc Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008)
    George G Zhanel
    Clinical Microbiology, Health Sciences Centre, 820 Sherbrook St, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 54:4684-93. 2010
    ..The prevalence of MRSA was 27.0% (of which genotypically 27.6% were CA-MRSA), while ESBL-producing E. coli occurred in 4.9% of isolates. An MDR phenotype was common in P. aeruginosa...
  8. pmc Antimicrobial resistance in urinary tract pathogens in Canada from 2007 to 2009: CANWARD surveillance study
    James A Karlowsky
    Diagnostic Services of Manitoba Department of Clinical Microbiology, Health Sciences Centre, St Boniface General Hospital, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 55:3169-75. 2011
    ..005). We conclude that frequently prescribed empirical agents for urinary tract infections, such as SXT and ciprofloxacin, demonstrate lowered in vitro susceptibilities when tested against recent clinical isolates...
  9. doi Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:364-9. 2009
    ..This study compared the pharmacodynamics of ceftobiprole and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant S. aureus (VRSA) using an in vitro model...
  10. pmc Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 52:1430-7. 2008
    ..aeruginosa, H. influenzae, Enterococcus spp., S. pneumoniae, and K. pneumoniae are the most common isolates recovered from clinical specimens in Canadian ICUs. A MDR phenotype is common for P. aeruginosa isolates in Canadian ICUs...
  11. doi Ceftaroline pharmacodynamic activity versus community-associated and healthcare-associated methicillin-resistant Staphylococcus aureus, heteroresistant vancomycin-intermediate S. aureus, vancomycin-intermediate S. aureus and vancomycin-resistant S. aureus
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Antimicrob Chemother 66:1301-5. 2011
    ..aureus (hVISA), VISA and vancomycin-resistant S. aureus (VRSA) using an in vitro model...
  12. doi Evolution and molecular characterization of macrolide-resistant Streptococcus pneumoniae in Canada between 1998 and 2008
    Aleksandra K Wierzbowski
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada
    J Antimicrob Chemother 69:59-66. 2014
    ....
  13. doi Antimicrobial susceptibility of 22746 pathogens from Canadian hospitals: results of the CANWARD 2007-11 study
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    J Antimicrob Chemother 68:i7-22. 2013
    ..The purpose of the CANWARD study was to assess the antimicrobial activity of a variety of available agents against 22,746 pathogens isolated from patients in Canadian hospitals between 2007 and 2011...
  14. doi Comparison of pathogens and their antimicrobial resistance patterns in paediatric, adult and elderly patients in Canadian hospitals
    Heather J Adam
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    J Antimicrob Chemother 68:i31-7. 2013
    ..The purpose of this study was to describe the association between age groups and antimicrobial resistance in the most commonly identified pathogens in Canadian hospitals...
  15. doi Trends in antibiotic resistance over time among pathogens from Canadian hospitals: results of the CANWARD study 2007-11
    Philippe R S Lagacé-Wiens
    Department of Microbiology, St Boniface General Hospital Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R2H 2A6
    J Antimicrob Chemother 68:i23-9. 2013
    ....
  16. doi Antimicrobial susceptibility of 15,644 pathogens from Canadian hospitals: results of the CANWARD 2007-2009 study
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba, Winnipeg, Manitoba, Canada R3E 0J9
    Diagn Microbiol Infect Dis 69:291-306. 2011
    ....
  17. doi Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems us
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    J Antimicrob Chemother 64:824-8. 2009
    ..This study assessed the in vitro pharmacodynamic activity of tigecycline against E. coli with ESBLs, AmpCs and CRS...
  18. ncbi Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Am J Clin Dermatol 9:245-54. 2008
    ..Further clinical studies are needed to determine the efficacy and safety of ceftobiprole and to define its role in patient care...
  19. doi Ceftaroline: a novel broad-spectrum cephalosporin with activity against meticillin-resistant Staphylococcus aureus
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 69:809-31. 2009
    ..Further clinical studies are needed to determine the efficacy and safety of ceftaroline, and to define its role in patient care...
  20. pmc Fluoroquinolone-resistant urinary isolates of Escherichia coli from outpatients are frequently multidrug resistant: results from the North American Urinary Tract Infection Collaborative Alliance-Quinolone Resistance study
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Canada
    Antimicrob Agents Chemother 50:2251-4. 2006
    ..0%) or nitrofurantoin (4.0%) was less common. Only 10.8% of isolates were resistant to ciprofloxacin alone. Fluoroquinolone-resistant isolates of E. coli from urine were frequently multidrug resistant...
  21. doi Assessment of the activity of ceftaroline against clinical isolates of penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, MS673 Health Sciences Centre, 820 Sherbrook Street, Winnipeg R3A 1R9, Canada
    J Antimicrob Chemother 67:1706-11. 2012
    ..This study assessed the pharmacodynamics of ceftaroline against penicillin-intermediate and penicillin-resistant Streptococcus pneumoniae with elevated MICs of ceftaroline using an in vitro pharmacodynamic model...
  22. doi Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Drugs 73:159-77. 2013
    ..Finally, the increased activity of ceftazidime-avibactam versus P. aeruginosa may be of clinical benefit in patients with suspected or documented P. aeruginosa infections...
  23. doi Prevalence of antimicrobial resistant pathogens from blood cultures from Canadian hospitals: results of the CANWARD 2007-2009 study
    Heather J Adam
    Department of Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba R3A 1R9, Canada
    Diagn Microbiol Infect Dis 69:307-13. 2011
    ..9%]). The most active agents against Gram-negative bacilli were carbapenems (e.g., meropenem and ertapenem) and piperacillin-tazobactam, while for Gram-positive cocci, they were vancomycin, linezolid, and daptomycin...
  24. doi In vitro activity of ceftobiprole against frequently encountered aerobic and facultative Gram-positive and Gram-negative bacterial pathogens: results of the CANWARD 2007-2009 study
    Andrew Walkty
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    Diagn Microbiol Infect Dis 69:348-55. 2011
    ..The broad spectrum of activity by ceftobiprole would support further study of this agent in the treatment of hospital-acquired infections...
  25. doi Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada ca
    Expert Rev Anti Infect Ther 10:459-73. 2012
    ....
  26. ncbi Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination
    Alfred Gin
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Canada
    Expert Rev Anti Infect Ther 5:365-83. 2007
    ..Piperacillin-tazobactam has an excellent safety and tolerability profile and continues to be a reliable option for the empiric treatment of moderate-to-severe infections in hospitalized patients...
  27. doi Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent
    George G Zhanel
    Department of Medical Microbiology, College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 76:567-88. 2016
    ..Eravacycline is a promising intravenous and oral fluorocycline that may offer an alternative treatment option for patients with serious infections, particularly those caused by multidrug-resistant Gram-negative pathogens. ..
  28. doi Annual macrolide prescription rates and the emergence of macrolide resistance among Streptococcus pneumoniae in Canada from 1995 to 2005
    James A Karlowsky
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Int J Antimicrob Agents 34:375-9. 2009
    ..Resistance development is complex and factors other than macrolide use may also be associated with observed increases in macrolide resistance in Canada from 1995 to 2005...
  29. doi Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    Drugs 74:31-51. 2014
    ..aeruginosa infections with this agent. Currently, ceftolozane/tazobactam is being evaluated in three phase III trials for the treatment of cUTI, cIAI, and VABP. ..
  30. doi Multidrug-resistant North American pulsotype 2 Clostridium difficile was the predominant toxigenic hospital-acquired strain in the province of Manitoba, Canada, in 2006-2007
    James A Karlowsky
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada 24
    J Med Microbiol 61:693-700. 2012
    ..2 vs 9.1%) in Manitoba in 2006-2007, and these isolates demonstrated high levels of clonality and multidrug resistance, and were associated with hospital acquisition...
  31. pmc In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre, MS673 820 Sherbrook St, Winnipeg, Manitoba R3A1R9, Canada
    Antimicrob Agents Chemother 55:2837-46. 2011
    ..Overall, ceftaroline demonstrated potent in vitro activity against a recent collection of the most frequently encountered Gram-positive and Gram-negative isolates from patients attending hospitals across Canada in 2009...
  32. doi Antimicrobial susceptibility of Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals: CANWARD 2008-2011
    Andrew Walkty
    Department of Medicine, Health Sciences Centre, Winnipeg, Manitoba, Canada
    Diagn Microbiol Infect Dis 73:361-4. 2012
    ..4%, gentamicin 76.8%, meropenem 82.7%, and piperacillin-tazobactam 83.6%. Antimicrobial susceptibility did not change significantly between 2008 and 2011, with the exception of increasing susceptibility to gentamicin (P < 0.0001)...
  33. ncbi Genetic relatedness of multidrug-resistant Escherichia coli cultured from geographically diverse outpatient, midstream urine specimens
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada R3A 1R9
    Diagn Microbiol Infect Dis 58:283-7. 2007
    ..Antimicrobial-susceptible isolates demonstrated limited genetic relatedness, whereas 2 epidemiologic clusters containing a total of 40 isolates (57.1%) were identified among the multidrug-resistant isolates...
  34. doi Baseline epidemiology of Streptococcus pneumoniae serotypes in Canada prior to the introduction of the 13-valent pneumococcal vaccine
    Heather J Adam
    Clinical Microbiology, Health Sciences Centre, Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada
    Microb Drug Resist 18:176-82. 2012
    ..5% of MDR-S. pneumoniae were covered by PCV-13. Accordingly, PCV-13 will provide coverage against a significant proportion of circulating S. pneumoniae strains in Canada, including the critical antimicrobial-resistant strains...
  35. pmc AFN-1252, a FabI inhibitor, demonstrates a Staphylococcus-specific spectrum of activity
    James A Karlowsky
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 53:3544-8. 2009
    ..Enterobacteriaceae, nonfermentative gram-negative bacilli, and Moraxella catarrhalis. These data support the continued development of AFN-1252 for the treatment of patients with resistant staphylococcal infections...
  36. doi Characterization of MDR and XDR Streptococcus pneumoniae in Canada, 2007-13
    Alyssa R Golden
    Department of Medical Microbiology, College of Medicine, Faculty of Health Sciences, University of Manitoba, 727 McDermot Avenue, Winnipeg, Manitoba R3E 3P5, Canada
    J Antimicrob Chemother 70:2199-202. 2015
    ....
  37. doi Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada
    Drugs 75:253-70. 2015
    ..Tedizolid is currently undergoing additional Phase III clinical trials for the treatment of hospital-acquired bacterial pneumonia (HABP) and ventilated nosocomial pneumonia (VNP)...
  38. pmc Identification of blood culture isolates directly from positive blood cultures by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry and a commercial extraction system: analysis of performance, cost, and turnaround time
    Philippe R S Lagacé-Wiens
    Department of Medical Microbiology and Infectious Diseases, University of Manitoba Winnipeg, Manitoba, Canada
    J Clin Microbiol 50:3324-8. 2012
    ..However, the use of MALDI-TOF for direct identification is accurate and should result in reduced turnaround time to identification...
  39. pmc In Vitro activity of fosfomycin against Escherichia coli isolated from patients with urinary tract infections in Canada as part of the CANWARD surveillance study
    James A Karlowsky
    Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 58:1252-6. 2014
    ..The concentrations of fosfomycin inhibiting 50 and 90% of the isolates were ≤1 and 4 μg/ml; 99.4% of the isolates were susceptible to fosfomycin. ..
  40. pmc Characterization of methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci and extended-spectrum beta-lactamase-producing Escherichia coli in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba
    Can J Infect Dis Med Microbiol 19:243-9. 2008
    ..Methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and vancomycin-resistant enterococci (VRE) are important hospital pathogens in Canada and worldwide...
  41. pmc In vitro activity of ceftazidime-avibactam against 338 molecularly characterized gentamicin-nonsusceptible Gram-negative clinical isolates obtained from patients in Canadian hospitals
    Andrew J Denisuik
    Department of Medical Microbiology and Infectious Diseases, College of Medicine, Faculty of Health Sciences, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 59:3623-6. 2015
    ..5 μg/ml (MIC, ≤8 μg/ml for 100% of isolates) and 16 μg/ml (MIC, ≤8 μg/ml for 87.8% of isolates) against gentamicin-nonsusceptible Enterobacteriaceae and P. aeruginosa isolates, respectively...
  42. pmc CHROMagar Orientation medium reduces urine culture workload
    Kanchana Manickam
    Diagnostic Services of Manitoba, University of Manitoba, Winnipeg, Manitoba, Canada
    J Clin Microbiol 51:1179-83. 2013
    ..88 in 2011 (postimplementation of CO medium). We conclude that the use of CO medium streamlined the urine culture process and increased bench throughput by reducing both workload and turnaround time in our laboratories...
  43. ncbi Comparative review of the carbapenems
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 67:1027-52. 2007
    ..aeruginosa than meropenem. Clinical trials are required to establish the efficacy and safety of doripenem in moderate to severe infections, including nosocomial infections...
  44. doi Dalbavancin and telavancin: novel lipoglycopeptides for the treatment of Gram-positive infections
    George G Zhanel
    MS 673 Microbiology, Health Sciences Centre, 820 Sherbrook Street, Winnipeg, Manitoba, R3A 1R9, Canada
    Expert Rev Anti Infect Ther 6:67-81. 2008
    ..Both telavancin and dalbavancin show promise as alternative treatments for patients with serious infections caused by resistant Gram-positive pathogens...
  45. pmc Prevalence of antimicrobial resistance among clinical isolates of Bacteroides fragilis group in Canada in 2010-2011: CANWARD surveillance study
    James A Karlowsky
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, a and Diagnostic Services of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 56:1247-52. 2012
    ..M. Bourgault et al., Antimicrob. Agents Chemother. 36:343-347, 1992), rates of resistance have increased for amoxicillin-clavulanate, from 0.8% (1992) to 6.2% (2010-2011), and for clindamycin, from 9% (1992) to 34.1% (2010-2011)...
  46. pmc In vitro activity of OPT-80 tested against clinical isolates of toxin-producing Clostridium difficile
    James A Karlowsky
    Department of Clinical Microbiology, Health Sciences Centre, MS673C, 820 Sherbrook Street, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 52:4163-5. 2008
    ..06 to 1 microg/ml, with 90% of the isolates inhibited by a concentration of 0.5 microg/ml. The in vitro activity of OPT-80 was independent of the susceptibilities of isolates to nine other antimicrobial agents...
  47. pmc In vitro activity of Iclaprim against respiratory and bacteremic isolates of Streptococcus pneumoniae
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Antimicrob Agents Chemother 53:1690-2. 2009
    ..The potential clinical utility of iclaprim to treat patients with pneumococcal infections may depend upon the current prevalence of resistance to trimethoprim-sulfamethoxazole in this pathogen...
  48. ncbi Antibiotic resistance in Escherichia coli outpatient urinary isolates: final results from the North American Urinary Tract Infection Collaborative Alliance (NAUTICA)
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, and Department of Medicine, Health Sciences Centre, Winnipeg, Man, Canada
    Int J Antimicrob Agents 27:468-75. 2006
    ..This study reports higher rates of antibiotic resistance in US versus Canadian outpatient urinary isolates of E. coli and demonstrates the continuing evolution of resistance to antimicrobial agents...
  49. ncbi In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species
    James A Karlowsky
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Man, Canada R3A 1R9
    Int J Antimicrob Agents 27:174-7. 2006
    ..These results suggest additional studies are warranted, for example in animal models, to evaluate further the potential of combination antifungal therapy with anidulafungin for Candida infections...
  50. ncbi Tigecycline: a novel glycylcycline antibiotic
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, Health Sciences Centre, University of Manitoba, Winnipeg, Manitoba, Canada
    Expert Rev Anti Infect Ther 4:9-25. 2006
    ..e., nausea, vomiting and diarrhea) the most commonly reported. Tigecycline is a promising new broad-spectrum parenteral monotherapy for the treatment of patients with Gram-positive and -negative bacterial infections...
  51. doi Oritavancin: mechanism of action
    George G Zhanel
    Department of Medical Microbiology, University of Manitoba, Winnipeg, Manitoba, Canada
    Clin Infect Dis 54:S214-9. 2012
    ....
  52. ncbi Role of efflux mechanisms on fluoroquinolone resistance in Streptococcus pneumoniae and Pseudomonas aeruginosa
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Manitoba, Canada
    Int J Antimicrob Agents 24:529-35. 2004
    ..In the meantime, appropriate antibiotic selection and optimal dosing strategies should aim to eradicate the causative pathogen before a resistant efflux mutant can emerge...
  53. pmc Evaluation of five chromogenic agar media and the Rosco Rapid Carb screen kit for detection and confirmation of carbapenemase production in Gram-negative bacilli
    Patricia J Simner
    Diagnostic Services Manitoba, Winnipeg, Manitoba, Canada University of Manitoba, Department of Medical Microbiology and Infectious Diseases, Winnipeg, Manitoba, Canada
    J Clin Microbiol 53:105-12. 2015
    ..8% and a specificity of 100%. As an optional component of the workflow, a determination of carbapenemase gene class via molecular means could be performed subsequent to confirmatory testing. ..
  54. doi Clinical cure rates in subjects treated with azithromycin for community-acquired respiratory tract infections caused by azithromycin-susceptible or azithromycin-resistant Streptococcus pneumoniae: analysis of Phase 3 clinical trial data
    George G Zhanel
    Department of Medical Microbiology and Infectious Diseases, Faculty of Medicine, University of Manitoba, Winnipeg, Canada
    J Antimicrob Chemother 69:2835-40. 2014
    ..This study assessed clinical cure rates in azithromycin-treated subjects with CARTI caused by azithromycin-susceptible (Azi-S) or azithromycin-resistant (Azi-R) SPN...
  55. ncbi Pyogenic liver abscess caused by hypermucoviscous Klebsiella pneumoniae
    Yoav Keynan
    Department of Medical Microbiology, University of Manitoba, Winnipeg, MB, Canada
    Scand J Infect Dis 39:828-30. 2007
    ..We describe a case of PLA caused by the hypermucoviscous, K1 capsular serotype of Klebsiella pneumoniae in a Canadian man and highlight the unique features of this increasingly common cause of liver abscess...
  56. ncbi The glycylcyclines: a comparative review with the tetracyclines
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    Drugs 64:63-88. 2004
    ..e. nausea, vomiting and headache). Tigecycline appears to be a promising new antibacterial based on in vitro and pharmacokinetic/pharmacodynamic activity; however more clinical data are needed to fully evaluate its potential...